3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Adenocarcinoma
1
Interventions
Carboplatin
27
pembrolizumab
26
Cisplatin
24
Paclitaxel
21
Nivolumab
19
Gemcitabine
16
Pemetrexed
14
Rituximab
14
Ipilimumab
12
Cyclophosphamide
11
Dexamethasone
11
Fluorouracil
10
Capecitabine
9
Docetaxel
9
durvalumab
9
trastuzumab deruxtecan
9
Lenalidomide
8
Oxaliplatin
8
atezolizumab
8
Doxorubicin
7
daratumumab
7
osimertinib
7
Bortezomib
6
Cytarabine
6
Leucovorin
6
Trastuzumab
6
olaparib
6
venetoclax
6
130-nm albumin-bound paclitaxel
5
Ado-Trastuzumab Emtansine
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
tepotinib
×
1 year
×
Clear all
NCT02864992
2026-04-13
VISION
EMD Serono
Phase 2
Active not recruiting
337 enrolled
13 charts
2 FDA